Screener
Discontinued — last reported Q3 '23
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed November 9, 2023.
- Filed
- Nov 9, 2023, 8:05 AM EST
- Fiscal quarter
- Q3 FY2023
- Calendar quarter
- Q3 2023
- Accession
- 0000950170-23-061554
| Line item | Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development (includes related party amounts of $130, $77, $538 and $1,800, respectively) | $12,263 | $19,020 | $36,505 | $55,495 |
| General and administrative (includes related party amounts of $14, $0, $30 and $0, respectively) | 23,396 | 23,509 | 60,932 | 70,303 |
| Total operating expenses | 35,659 | 42,529 | 97,437 | 125,798 |
| Loss from operations | (35,659) | (42,529) | (97,437) | (125,798) |
| Other income (expense): | ||||
| Interest income | 2,720 | 726 | 4,528 | 845 |
| Interest expense | (10,107) | (9,277) | (28,939) | (17,703) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Phathom Pharmaceuticals, Inc.'s G&A?
- Phathom Pharmaceuticals, Inc. (PHAT) reported G&A of $23.4M in Q3 2023.
- How has Phathom Pharmaceuticals, Inc.'s G&A changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s G&A decreased by 0.5% year-over-year, from $23.51M to $23.4M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Phathom Pharmaceuticals, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude